Minerva Biotechnologies

Developing therapies for curing #cancers and core technology that will enable next generation #stemcell therapies.

[Minerva Biotechnologies @MinervaBio]

Overcoming the Solid Tumor Barrier: MUC1*-Targeted CAR T bearing 1XX mutations overcomes exhaustion enables killing of low antigen expressing cancer cells
Minerva Biotechnologies’ just published https://t.co/gvmUEjLAwU breakthrough for treatment of solid tumors

[Minerva Biotechnologies @MinervaBio]

Open Chemist Position,
We are seeking a talented and highly motivated individual to join the chemistry group at Minerva Biotechnologies in Waltham. Apply to [email protected] with CV/resume or to find out more.

[Minerva Biotechnologies @MinervaBio]

Minerva Biotechnologies: FDA approves 2nd IND for MUC1*-targeting CAR-T that persists longer & can kill low antigen expressing cancer cells. MUC1* (muk 1 star) is growth factor receptor that drives growth & metastasis of most solid tumor cancers. NCT04020575 for breast cancers.

[Minerva Biotechnologies @MinervaBio]

Immediate openings for BS, MS, and PhD level scientists! Send a brief cover letter and CV to [email protected] 🔬🥼

[Minerva Biotechnologies @MinervaBio]

Recruiting @HarvardGSAS on Friday, October 15! See you there!

[Minerva Biotechnologies @MinervaBio]

BS/MS Level Scientist Position
Immediate openings for BS/MS scientists to work in the exciting field of cancer immunotherapy. Collaborative, team-oriented culture. Background in Biology, Biochemistry, Biotech, or Immunohistochemistry ideal. Please sendCV to [email protected]

[Minerva Biotechnologies @MinervaBio]

PhD Level Scientist Position
Seeking candidates with organized, yet unconstrained, thought processes. Immediate openings for PhD level scientists to join a collaborative scientific team working at the cutting edge of cancer immunotherapy. Please send CV to [email protected]

[Minerva Biotechnologies @MinervaBio]

Minerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Technology

https://t.co/UQsYooI391

[Minerva Biotechnologies @MinervaBio]

Join us for our poster "1st-In-Human CAR T Targets MUC1 Transmembrane Cleavage Product" at virtual #asgct2020 #ASGCT20. Dr. Cynthia Bamdad will be online from 5:30-6:30 today. Poster is #757.

[Minerva Biotechnologies @MinervaBio]

Minerva's First-in-Human CAR T clinical trial in breast cancer is featured in this article: https://t.co/lVGxKz69WY

[Minerva Biotechnologies @MinervaBio]

Are you going to the Precision Medicine World Conference @PMWCintl in January 2020?

Join our CEO @CBamdad to learn about a 1st-in-Human CAR-T for solid tumors that targets a Cleaved MUC1.

Registration and program details: https://t.co/t9ShMV83Sy

#PMWC20

[Minerva Biotechnologies @MinervaBio]

Minerva Biotechnologies Announces FDA Acceptance of IND Application for huMNC2-CAR44 T cells to Treat Metastatic Breast Cancer #cart #cartcells #cancer #breastcancer https://t.co/nKiAtLgrPo

[Minerva Biotechnologies @MinervaBio]

Don't let FGF hold you back any longer! Learn about NME7AB, the growth factor naturally present in the early embryo. 11:30am today, Melbourne Room 1, Level 2 CEO @CBamdad will speak on the impact of various stem cell growth medias on lineage determination. Plus lunch! #ISSCR2018

[New York Stem Cell Foundation Research Institute @nyscf]

Great to hang out with @CoffeyPete, @ParmarLab, @jeannefrances & @MinervaBio folks at the #ISSCR2018 NYSCF booth!

[ACEA Biosciences @aceabiosciences]

Dr. Bamdad has developed a CAR-T cell therapy for solid tumors that will be proceeding to human clinical trials this year. Our #Cancer #Immunotherapy Symposium in Chicago will be featuring leading scientists in T cell therapy. Register at https://t.co/riF0bgI6qF with promo EARLY

[Minerva Biotechnologies @MinervaBio]

Minerva Biotechnologies will present a poster entitled, “Anti-MUC1* CAR T for solid tumors” at #AACR18 - McCormick Place South, Exhibit Hall A, Poster Section 24: Adoptive Cell Therapies, Poster #2544, on Monday, 4/16 1-5 PM. Meet Dr. Bamdad and the Minerva team!

[Minerva Biotechnologies @MinervaBio]

Minerva Biotechnologies Announces CellSystems as European Distributor of AlphaSTEM™, Naïve Stem Cell Culture System - https://t.co/rN4ALOsyBg

[Minerva Biotechnologies @MinervaBio]

Check out the latest issue of our newsletter featuring articles from @biocompare, @StemCellMarket, and @CellCultureDish
https://t.co/eiWim5sDtl

[Minerva Biotechnologies @MinervaBio]

Read about #stemcells advances, including AlphaSTEM @biocompare article Advances in iPS Cells: Tools & Applications https://t.co/EgAxDeJCUk

[Minerva Biotechnologies @MinervaBio]

Naïve iPSC Generation, Expansion & Differentiation Using the AlphaSTEM™ System #stemcells #ipsc #neurons
https://t.co/x6GBYLykgh